[ad_1]
Sol Gel Technologies (NASDAQ: SLGL) and Perrigo (NYSE: PRGO) are both medical companies, but what is the best stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, dividends, badyst recommendations and valuation.
Profitability
Chart compares net margins, return on equity and return on badets of Sol Gel Technologies and Perrigo
| Net Margins | Return on Equity | Return on Assets [19659007] Sol Gel Technologies [19659008] N / A | N / A | N / A | |
| Perrigo | 2.59% | 11.93% | 6.23% % |
Earnings and Valuation
This table compares Sol Gel Technologies and revenue, earnings per share and market value of Perrigo
| Gross Revenue | Price / Sales Ratio | Net Income [19659005] Earnings per share | Price / earnings ratio | ||||||||||||||||||
| Sol Gel Technologies | $ 170,000.00 | 722.30 | – $ 31.56 million | ($ 5.02) [19659008] -1,29 | |||||||||||||||||
| Perrigo | $ 4.95 billion | 2.13 | $ 119.60 million | $ 4.93 | 15.42 [19659033] Perrigo has higher income and profits than Sol Gel Technologies. Sol Gel Technologies is trading at a price / earnings ratio lower than Perrigo's, which indicates that it is currently the most affordable of the two stocks.
Ownership of Insiders and Institutions 22.3% of Sol Gel Technologies shares are held by institutional investors. In comparison, 80.4% of Perrigo shares are held by institutional investors. 6.9% of Perrigo shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large fund managers believe that a stock will outperform the market in the long run Analyst Recommendations This is a breakdown of Sol Gel Technologies and Perrigo's current ratings and recommendations, as provided by MarketBeat.com.
Sol Gel Technologies currently has a consensus price target of 18.33 $, suggesting a upside potential of 182.49%. Perrigo has a consensus price target of $ 93.38, suggesting a potential upside of 22.83%. Given the highest consensus rating of Sol Gel Technologies and the likely higher rating, research badysts clearly believe that Sol Gel Technologies is more favorable than Perrigo. Dividends Perrigo pays an annual dividend of $ 0.76 per share and a dividend of 1.0%. Sol Gel Technologies does not pay a dividend. Perrigo pays 15.4% of its profits as a dividend. Perrigo has increased his dividend for 15 consecutive years. Abstract Perrigo beats Sol Gel Technologies on 11 of 15 factors compared between the two stocks. About Sol Gel Technologies <img src = "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?w=250&zc=1&src=https://www.marketbeat .com / logos / sol-gel-technologies-ltd-logo.png "alt =" Sol Gel Technologies logo "title =" Sol Gel Technologies logo "Sol-Gel Technologies Ltd., a specialty pharmaceutical company in the clinical phase, is dedicated to the development and commercialization of topical dermatological products based on its proprietary microencapsulation delivery system in Israel. The company's main product candidates include TWIN and SIRS -T, which has completed the Phase II clinical trials for the treatment of Acne vulgaris, and VERED who completed Phase II clinical trials for the treatment of papulopustular rosacea and who is also involved in the development of generic dermatological drug products. Ltd has collaborated with Perrigo and Douglas Pharmaceuticals for the development and commercialization of a generic product candidate. Nd's head office is in Ness Ziona, Israel. About Perrigo
Receive news and ratings of Sol Gel Technologies Daily – Enter your email address below to receive a concise summary of the latest news and ratings by badysts for Sol Gel Technologies and related companies with the free daily newsletter of MarketBeat.com. [ad_2]Source link Tags assessment capital cities Gel Perrigo PRGO SLGL Sol technologies Related Articles |
Perrigo Company plc, a health care company, manufactures and supplies -counter (OTC) health care products, infant formula, OTC branded products, and generic pharmaceuticals worldwide. The company operates through the Consumer Healthcare Americas, Consumer Healthcare International and Prescription Pharmaceuticals segments. It offers over-the-counter products for coughs, colds, allergies, sinuses, painkillers, smoking, infant formula and foods, animal health, diagnosis, lifestyle, personal care and dermatological, vitamins and antiparasitics. The company also develops, manufactures and markets a portfolio of generic medicines such as creams, ointments, lotions, gels, shampoos, foams, suppositories, sprays, liquids, suspensions, solutions, powders, controlled substances, injectables, hormones, solid dosage forms and oral liquid formulations. In addition, it offers contract manufacturing services. The company offers its products through retail chains of drugs, supermarkets and mbad merchandise; hospitals; pharmacies; wholesalers; pharmacies and grocery stores; and para pharmacies, as well as through a network of pharmacy sales force in North America, Europe, Australia, Israel and China. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland. 